Spain-based Portuguese Healthcare Company Biorce Raises €5 Million to Accelerate AI-Powered Clinical Trials

Led by Pedro Coelho(CEO & Founder), Clara Bernardes(Co-Founder & Chief Scientific Officer), Jose Faria(Co-Founder & Head of Engineering), Diogo Pisoeiro(Co-Founder & Chief Product Officer ), Dennis Velasquez(Head Of Clinical Solutions), Pia Sarrio(Head of Marketing), Katerina Dimitriadou(Marketing Manager), Mathias Haeusslein(Head of Business Operations & Performance), Xavi Carroza(Head of Cloud, Security & Data), Kara Booker(Lead Product Manager), Jake Lanier(Director of clinical solutions), Amir Davijani(Lead ML Engineer), & others, Biorce has raised €5 Million from Norrsken VC, bringing Biorce’s total funding to €8.5 million, as reported in TFN.

Biorce will use the funding to accelerate U.S. expansion, enhance product development, and grow its engineering and commercial teams as it targets eight-digit revenue. Operating in Spain, the UK, and the Nordics, the company has doubled in size since late 2024, driven by rising demand for smarter clinical trial solutions.

Jarvis, Biorce’s AI-native platform, transforms clinical trial planning by predicting delays, optimizing site selection, and refining protocols in real time. Already used in oncology and neurology trials, it reduces protocol amendments by up to 50% and shortens timelines by up to 70%, saving sponsors millions and accelerating patient access to new therapies.

Biorce has rapidly emerged as a key player in clinical trial planning, moving from concept to adoption in just over a year. As drug development grows more complex, its AI platform, Jarvis, is redefining how trials are designed, starting with smarter planning, not just better science.